Skip to main content

ADVERTISEMENT

chronic lymphocytic leukemia

Clinical Images
02/15/2024
A 53-year-old female was admitted to the cardiology department on account of signs and symptoms of congestive heart failure with severe peripheral edema and dyspnea on exertion (New York Heart Association class III) for the past 3 months.
A 53-year-old female was admitted to the cardiology department on account of signs and symptoms of congestive heart failure with severe peripheral edema and dyspnea on exertion (New York Heart Association class III) for the past 3 months.
A 53-year-old female was...
02/15/2024
Journal of Invasive Cardiology
Research Reports
06/21/2022
Dr Davids and colleagues estimated the total cumulative costs per patient of treatment sequences for adults with chronic lymphocytic leukemia, with and without deletion 17p, as well as the budget impact of introducing sequences with...
Dr Davids and colleagues estimated the total cumulative costs per patient of treatment sequences for adults with chronic lymphocytic leukemia, with and without deletion 17p, as well as the budget impact of introducing sequences with...
Dr Davids and colleagues...
06/21/2022
Journal of Clinical Pathways
Conference Coverage
12/09/2020
Journal of Clinical Pathways
Novel Ibrutinib Combination for Primary Treatment of CLL
Interview
06/22/2020
On April 21, 2020, the FDA expanded its approval of ibrutinib to include its use in combination with rituximab for the primary treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
On April 21, 2020, the FDA expanded its approval of ibrutinib to include its use in combination with rituximab for the primary treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
On...
06/22/2020
Journal of Clinical Pathways
04/04/2016
JCP Editors
Recent Food and Drug Administration (FDA) approvals have changed the landscape of treatment for chronic lymphocytic leukemia (CLL). In a session at the 2016 National Comprehensive Cancer Network (NCCN) Annual...
Recent Food and Drug Administration (FDA) approvals have changed the landscape of treatment for chronic lymphocytic leukemia (CLL). In a session at the 2016 National Comprehensive Cancer Network (NCCN) Annual...
Recent...
04/04/2016
Journal of Clinical Pathways